parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (662 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 14956

LANCL1 in dopamine neurons, braak+0.47 (p 0.199) → +0.06 (p 0.874)receipt 14963
LANCL1 in oligodendrocytes, braak+0.39 (p 0.297) → +0.11 (p 0.778)receipt 14962

receipt 14963: LANCL1 in dopamine neurons, braak

power: full sample +0.27 (p 0.281, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.365, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.50 (p 0.033, n 18). not the mix.
skeptic: leave-one-out range +0.17 to +0.44, sign flips 0; without severely affected donors +0.27 (p 0.281, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LANCL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14962: LANCL1 in oligodendrocytes, braak

power: full sample +0.23 (p 0.360, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.360, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.18 (p 0.482, n 18). could be the mix.
skeptic: leave-one-out range +0.14 to +0.38, sign flips 0; without severely affected donors +0.23 (p 0.360, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LANCL1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts